On May 23, 2018, Hansoh’s antifungal drug Hengsen (Micafungin Sodium for Injection) received NDA approval from National Medical Products Administration.

Micafungin sodium is a semi-synthetic lipopeptide compound that competitively inhibits the synthesis of 1,3-β-D glucan, an essential component of the fungal cell wall. It is used to treat fungal diseases caused by Aspergillus and Candida, respiratory fungal diseases, and gastrointestinal fungal infections.